A demonstration area for type 2 diabetes prevention in Barranquilla and Juan Mina (Colombia)

Abstract

Type 2 diabetes (T2D) imposes a heavy public health burden in both developed and developing countries. It is necessary to understand the effect of T2D in different settings and population groups. This report aimed to present baseline characteristics of study participants in the demonstration area for the “Type 2 Diabetes Prevention in Barranquilla and Juan Mina” (DEMOJUAN) project after randomization and to compare their fasting and 2-hour glucose levels according to lifestyle and T2D risk factor levels.The DEMOJUAN project is a randomized controlled field trial. Study participants were recruited from study sites using population-wide screening using the Finnish Diabetes Risk Score (FINDRISC) questionnaire. All volunteers with FINDRISC of ≥13 points were invited to undergo an oral glucose tolerance test (OGTT). Participant inclusion criteria for the upcoming field trial were either FINDRISC of ≥13 points and 2-hour post-challenge glucose level of 7.0 to 11.0 mmol/L or FINDRISC of ≥13 points and fasting plasma glucose level of 6.1 to 6.9 mmol/L. Lifestyle habits and risk factors for T2D were assessed by trained interviewers using a validated questionnaire.Among the 14,193 participants who completed the FINDRISC questionnaire, 35% (n = 4915) had a FINDRISC score of ≥13 points and 47% (n = 2306) agreed to undergo the OGTT. Approximately, 33% (n = 772) of participants underwent the OGTT and met the entry criteria; these participants were randomized into 3 groups. There were no statistically significant differences found in anthropometric or lifestyle risk factors, distribution of the glucose metabolism categories, or other diabetes risk factors between the 3 groups (P > .05). Women with a past history of hyperglycaemia had significantly higher fasting glucose levels than those without previous hyperglycaemia (103 vs 99 mg/dL; P < .05).Lifestyle habits and risk factors were evenly distributed among the 3 study groups. No differences were found in fasting or 2-hour glucose levels among different lifestyle or risk factor categories with the exception of body mass index, past history of hyperglycaemia, and age of ≥64 years in women.Trial registration: NCT01296100 (2/12/2011; Clinical trials.gov).

Identifying diabetes risks among Indonesians: A cross-sectional study in a community setting

“…The strategy used to determine the number of samples was the same as that used in similar studies (Israel, 2003 ). The samples were 15% of the total population, following a similar study conducted by Acosta et al ( 2018 ). With a population of 8,024 older adults in the district of Deli Tua, Deli Serdang Regency, North Sumatra Province, Indonesia, the sample size was 1,216 persons (Deli Serdang Regency Central Statistics Agency, 2018 ).…”

Early Lifestyle Interventions in People with Impaired Glucose Tolerance in Northern Colombia: The DEMOJUAN Project

“…The design of the DEMOJUAN study was a three-arm, parallel-group, randomized, and controlled field trial, using individual random allocation, and was carried out in Juan Mina and Barranquilla, Northern Colombia [19]. The study site had approximately 1 million inhabitants at the time of participant recruitment.…”

“…Furthermore, it also detects reasonably prevalent asymptomatic T2D and other disorders of glucose metabolism [23]. The FINDRISC has been validated in many populations with good results [24,25,26,27] and has been successfully applied in primary care in Barcelona, Spain [19]. It is recommended by the International Diabetes Federation and in the guideline by the European Society for the Study of Diabetes and the European Society of Cardiology as a screening tool for T2D [28,29].…”

Findrisc, Utility in the Screening of Diabetes, Personalization and Associations

“…En el estudio realizado por Acosta T, Barengo NC, Arrieta A, Ricaurte C, Tuomilehto JO. 32 Establecieron que el FINDRISC es clave para la prevención primaria y en la detección precoz de diabetes, como segundo paso sería tomar un test de tolerancia a la glucosa.…”